Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.

You may also be interested in...



Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally

FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel